Soros Fund Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Soros Fund Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,800	Closed	-$218K	–	282
2017 Q2	$218K	Buy	+1,800	New	+$209K	﹤0.01%	192
2016 Q4	–	Sell	-3,623	Closed	-$596K	–	303
2016 Q3	$596K	Sell	3,623 -4,477	-55%	-$706K	0.01%	156
2016 Q2	$1.16M	Buy	+8,100	New	+$1.18M	0.02%	125
2016 Q1	–	Sell	-2,800	Closed	-$418K	–	330
2015 Q4	$418K	Buy	+2,800	New	+$474K	0.01%	204

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Soros Fund Management's ICPT Position: Q3 2017 in Review

Soros Fund Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2017, closing a stake of 1,800 shares — an estimated $218K sold.

Soros Fund Management first reported a position in ICPT in Q4 2015 and held it in 4 quarters. The position peaked at $1.16M in Q2 2016. 155 funds tracked by Wall St. Rank hold ICPT as of Q3 2017.

Soros Fund Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Soros Fund Management sold 1,800 Intercept Pharmaceuticals, Inc. shares in Q3 2017, an estimated $218K.
Soros Fund Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2015 and held it in 4 quarters.
Soros Fund Management's Intercept Pharmaceuticals, Inc. position peaked at $1.16M in Q2 2016.
155 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2017.

Based on Soros Fund Management's 13F filing for Q3 2017, filed 14 Nov 2017.